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Title 
Cell Salvage during Caesarean Section: A Randomised Controlled Trial (The SALVO Trial)  
Objective 
Excessive haemorrhage at caesarean section requires the use of donor (allogeneic) blood 
transfusion. The SALVO trial assessed whether the routine use of cell salvage during caesarean 
section can reduce the need for donor blood transfusion. 
Methods 
We conducted a randomised controlled trial (26 UK obstetric units; June 2013 through April 
2016) of routine cell salvage use (intervention) vs. current standard of care without routine 
salvage use (control) in caesarean section among women at risk of haemorrhage. We used 
multivariable models, adjusting for stratification variables and prognostic factors identified a 
priori, to compare rates of donor blood transfusion (primary outcome) and fetomaternal 
KDHPRUUKDJHPO LQ5K'-negative women with RhD-positive baby (one of the secondary 
outcomes) between groups. 
Results 
Of 3028 women randomised, 2990 were analysed (after exclusions for vaginal delivery or 
hospital transfer after randomisation). Of 1498 assigned to intervention, 95.6% had cell salvage 
deployed (50.8% had salvaged blood returned; mean 259.9 ml) vs. 3.9% of 1492 assigned to 
control. Donor blood transfusion rates were lower in the intervention group than in control 
(2.5% vs. 3.5%, adjusted odds ratio [OR] 0.65, 95% confidence interval [CI] 0.42 to 1.01). No 
case of amniotic fluid embolism was observed. Fetomaternal haemorrhage was higher with 
intervention vs. control (25.6% vs. 10.5%, adjusted OR 5.63, 95% CI 1.43 to 22.14).  
 Conclusion:  
There was modest evidence for an effect of routine use of cell salvage during caesarean section 
on donor blood transfusion. The increased fetomaternal haemorrhage emphasises the need for 
adherence to guidance on anti-D prophylaxis and for research on risks of alloimmunisation to 
RhD and other red cell antigens following cell salvage. (Funder: UK National Institute of 
Health Research Health Technology Assessment programme, ISRCTN66118656) 
 
